Mielóma multiplex: vizsgálatok itt: Románia
6 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Where
- Bucharest, Cluj-Napoca, Iași
- Életkor
- 18 év and over
- People
- 810 worldwide
- Run by
- Celgene
See details and how to joinNCT05519085 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Bucharest, Iași
- Életkor
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00 - 3. fázisTaking peopleA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Where
- Bucharest, Cluj-Napoca, Craiova
- Életkor
- 18 év and over
- People
- 183 worldwide
- Run by
- Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00 - 3. fázisTaking peopleA Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- Where
- Brasov, Bucharest, Cluj-Napoca, Iași, Ovidiu, Timisoara
- Életkor
- 18 év and over
- People
- 386 worldwide
- Run by
- Grifols Therapeutics LLC
See details and how to joinNCT05645107 · EU 2022-502193-16-00 - 1/2. fázisTaking peopleStudy to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- Where
- Bucharest, Cluj-Napoca
- Életkor
- 18 év and over
- People
- 78 worldwide
- Run by
- Heidelberg Pharma AG
See details and how to joinNCT04879043 · EU 2024-515273-10-00 - No phaseTaking peopleReal-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
- Where
- Bucharest, Cluj-Napoca, Craiova
- Életkor
- 18 év and over
- People
- 75 worldwide
- Run by
- Takeda
See details and how to joinNCT05879757